['primary hyperlipidemia and mixed dyslipidemia']
['atorvastatin', 'placebo to evolocumab', 'placebo to atorvastatin']

        Inclusion Criteria:

          -  Fasting LDL-C at screening ≥ 100 mg/dL and ≤ 190 mg/dL

          -  Fasting triglycerides ≤ 150 mg/dL

          -  Body mass index (BMI) between 18.0 and 32.0 kg/m^2

          -  Framingham cardiac risk score 10% or less

        Exclusion Criteria:

          -  Treatment with a lipid-regulating drug or over the counter supplement in the last 3
             months prior to screening

          -  History of coronary heart disease (CHD) or CHD equivalent

          -  Uncontrolled hypertension

          -  Diabetes mellitus
      